Somatostatin Imaging of Neuroendocrine-Differentiated Prostate Cancer

被引：1

作者：

Hope, Thomas A. ^{[1
]}

Aggarwal, Rahul ^{[2
]}

Simko, Jeff P. ^{[3
,4
,5
]}

VanBrocklin, Henry F. ^{[1
]}

Ryan, Charles J. ^{[2
]}

机构：

[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Div Hematol Oncol, Dept Med, San Francisco, CA 94143 USA

[3] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA

[4] Univ Calif San Francisco, Dept Urol, San Francisco, CA 94143 USA

[5] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA

来源：

CLINICAL NUCLEAR MEDICINE | 2015年 / 40卷 / 06期

关键词：

prostate cancer; octreotide; neuroendocrine; somatostatin; FDG;

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases. Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using In-111-labeled octreotide.

引用

页码：540 / 541

页数：2

共 50 条

[41] Pancreatic metastasis from locally recurrent neuroendocrine differentiated prostate cancer after radical prostatectomy
Ando, Takashi
Watanabe, Kazuhiro
Mizusawa, Takaki
Sakai, Takeshi
Katagiri, Akiyoshi
UROLOGY CASE REPORTS, 2020, 31
[42] Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Alberto Carmona-Bayonas
Paula Jiménez-Fonseca
Ana Custodio
Enrique Grande
Jaume Capdevila
Carlos López
Alex Teule
Rocío Garcia-Carbonero
Current Oncology Reports, 2017, 19
[43] Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Carmona-Bayonas, Alberto
Jimenez-Fonseca, Paula
Custodio, Ana
Grande, Enrique
Capdevila, Jaume
Lopez, Carlos
Teule, Alex
Garcia-Carbonero, Rocio
CURRENT ONCOLOGY REPORTS, 2017, 19 (11)
[44] Somatostatin receptor expression in neuroendocrine breast cancer
Terlevic, R.
Balja, M. Peric
Tomas, D.
Kruslin, B.
Vranic, S.
Skenderi, F.
Demirovic, A.
VIRCHOWS ARCHIV, 2018, 473 : S30 - S30
[45] NEUROENDOCRINE DIFFERENCIATION OF PROSTATE CANCER AND THE OUTCOMES OF EVEROLIMUS AGAINST NEUROENDOCRINE PROSTATE CANCER (NEPC)
Tatsuya, Shimomura
Kurauchi, Takashi
Keigo, Sakanaka
Kimura, Takahiro
Egawa, Shin
JOURNAL OF UROLOGY, 2018, 199 (04): : E700 - E700
[46] The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors
Hindie, Elif
THERANOSTICS, 2017, 7 (05): : 1159 - 1163
[47] Somatostatin receptor scintigraphy for neuroendocrine pattern in patients with hormone-refractory prostate cancer: Preliminary experience
不详
EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 93 - 93
[48] Ectopic acromegaly due to a growth hormone-secreting neuroendocrine-differentiated tumor developed from ovarian mature cystic teratoma
Mesut Ozkaya
Zeynel Abidin Sayiner
Gurkan Kiran
Kamile Gul
Ibrahim Erkutlu
Umut Elboga
Wiener klinische Wochenschrift, 2015, 127 : 491 - 493
[49] Ectopic acromegaly due to a growth hormone-secreting neuroendocrine-differentiated tumor developed from ovarian mature cystic teratoma
Ozkaya, Mesut
Sayiner, Zeynel Abidin
Kiran, Gurkan
Gul, Kamile
Erkutlu, Ibrahim
Elboga, Umut
WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 (11-12) : 491 - 493
[50] Neuroendocrine differentiation in prostate cancer
Jiaoti Huang Department of Pathology
Journal of Nanjing Medical University, 2008, (02) : 106 - 106

← 1 2 3 4 5 →